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ABSTRACT 
CO-LOCALIZATION OF POLYCYSTIC OVARY SYNDROME CANDIDATE GENE 
PRODUCTS IN HUMAN THECA CELLS SUGGESTS NOVEL SIGNALING PATHWAYS 
 
By REWA MAHESH KULKARNI, B.TECH 
 
A thesis submitted in partial fulfillment of the requirements for the degree of                                               
Master of Science Virginia Commonwealth University, 2019 
 
 
ADVISOR: DR. JEROME F. STRAUSS III, M.D., Ph.D. 
 
Professor of Obstetrics and Gynecology, Human and Molecular Genetics,  
Biochemistry and Molecular Biology, and Physiology and Biophysics 
Virginia Commonwealth University 
 
 
Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility, and the 
most common endocrinopathy of women of reproductive age.  Genome-wide association 
studies (GWAS) identified a number of loci associated PCOS in different ethnic 
populations, including women with Asian and European ancestry.  Replication studies 
have confirmed some of these associations.  Among the loci identified are those located 
near the LH receptor gene (LHCGR), a clathrin-binding protein gene (DENND1A) that 
also functions as a guanine nucleotide exchange factor, and the gene encoding RAB5B, 
a GTPase and protein involved in vesicular trafficking.  The functional significance of one 
of these GWAS candidates (DENND1A) was supported by our discovery that a truncated 
protein splice variant of DENND1A termed DENND1A.V2, is elevated in PCOS theca 
cells, and that forced expression of DENND1A.V2 in normal theca cells increased 
CYP11A1 and CYP17A1 expression and androgen synthesis, a hallmark of PCOS.  
PCOS GWAS loci could be assembled into a functional network that contributes to altered 
gene expression in ovarian theca cells, resulting in increased androgen synthesis.  This 
 x 
thesis demonstrates the localization of LHCGR, DENND1AV.2 and RAB5B proteins in 
various cellular compartments in normal and PCOS theca cells.  hCG and forskolin 
stimulation affects the distribution and co-localization of DENND1A.V2 and RAB5B in 
various cellular compartments This cytological evidence supports the PCOS gene 
network concept, and raises the intriguing possibility that LHCGR activation, via a cAMP-
mediated process, promotes the translocation of DENND1A.V2 and RAB5B-containing 
vesicles from the PCOS theca cell cytoplasm into the nucleus, resulting in increased 
transcription of genes involved in androgen synthesis.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
POLYCYSTIC OVARY SYNDROME (PCOS) 
 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of reproductive 
age women and the leading cause of anovulatory infertility. It is characterized by 
hyperandrogenism (increased levels of testosterone), anovulation, which leads to 
infertility, and the characteristic presence of multiple small subcortical follicular cysts, 
which detectable by transvaginal ultrasound (1,2).  PCOS is often accompanied by 
metabolic disturbances including insulin resistance and hyperinsulinemia (1,2). The 
etiology of PCOS is thought to be rooted in genetic and environmental factors (3) 
 
PCOS INCIDENCE AND DETECTION  
PCOS is believed to be prevalent in about 5-7% of reproductive age women(4–7), but 
these numbers may vary according to the diagnostic criteria. The three common 
diagnostic criteria used for the detection of PCOS were formulated by the: National 
Institutes of Health (NIH) Criteria, the Rotterdam Criteria, and the Androgen Excess 
Society (AES) (8). The NIH criteria include a combination of  hyperandrogenism along 
with oligo/amenorrhea anovulation (infrequent or absence of menstruation), the 
Rotterdam Criteria includes two out of three features; polycystic ovarian morphology 
(PCOM) seen on ultrasound and the two criteria mentioned in the NIH guidelines, 
whereas the AES criteria includes hyperandrogenism along with oligomenorrhea or 
PCOM or both (8). 
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PCOS TREATMENT 
There are a variety of treatment options available, and the standard treatment is oral 
contraceptives, if the woman is not seeking to become pregnant. For infertility, 
competitive aromatase inhibitors (e.g., Letrozole), which inhibit estrogen biosynthesis and 
result in an acute elevation of FSH, or estrogen receptor antagonists like clomiphene 
citrate, which also increases FSH, or FSH injections are effective in inducing follicular 
development in most women (9). These agents have been used along with other 
medications including dexamethasone or metformin (9). 
As many women with PCOS are overweight, leading to metabolic problems and insulin 
resistance, weight loss and use of insulin sensitizing agent like metformin seems to yield 
positive results. Recent studies show that a combination of myo-inositol and D-chiro-
inositol in a ratio of 10:1 is effective in improving the metabolic and hormonal aspects of 
women with PCOS (10).  
Other research has shown that natural product like Tetragonia tetragonioides (TTK), a 
medicinal plant which is being used for a long time to treat diabetic, inflammatory, and 
female-related disorders, can be used as a treatment for PCOS (11). This study shows 
that TTK extract had significantly reduced forskolin stimulated androgen production in 
NCI-H295R cells, and also reduced serum LH, testosterone and follicular cysts in a 
letrozole-induced PCOS mouse model (11). Thus, TTK could in future be possibly used 
in the treatment of PCOS.  
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Currently, the only long term solutions to treat PCOS are lifestyle and dietary changes 
along with weight loss. Thus, understanding the mechanism by which PCOS is initiated 
and progresses is key to finding better ways to treat PCOS. 
 
PCOS CAUSE AND PATHOPHISOLOGY 
 The pathophysiology underlying PCOS is not yet known, but it believed to be a 
multifactorial disorder, which may result from various environmental and genetic factors. 
Family-based and twin studies revealed a significant genetic contribution to PCOS 
(12,13). To understand the possible mechanisms involved in PCOS several different 
genome-wide association studies were performed in different demographics, with an aim 
to understand and possibly find a treatment for it. These genome-wide association studies 
(GWAS) have yielded more than 20 loci located near putative PCOS genes, including 
DENND1A, LHCGR, FSHR, ZNF217, YAP1, INSR, RAB5B, and C9orf3, being most 
critical among others (14–18).  A number of these loci have been replicated in GWAS or 
targeted genotyping studies in different populations(19,20). However, the specific 
variants associated with the PCOS phenotype or their functional significance remain to 
be identified for most of the PCOS candidates.  
 
DENND1A AND PCOS 
Among the candidate genes, the DENND1A locus at 9q22.32, was identified in both Asian 
and European ancestry populations in GWAS and replication studies (19,20). DENND1A 
is a member of the connecdenn family that encodes a clathrin-binding protein localized 
to coated pits, a clustering point for plasma membrane receptors (21). The DENN 
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(Differentially Expressed in Normal and Neoplastic cells) domain encodes a guanine 
nucleotide exchange function, which was previously shown to interact with RAB35, a 
small GTPase (21). The splice variant of DENND1A, termed DENND1A.V2, encodes a 
truncated molecule retaining the DENN and clathrin-biding domains, but lacks the proline-
rich domain which interacts with the adapter protein, growth factor receptor-bound protein 
2, and contains a unique 33 amino acid C-terminus (Fig. 1) (22,23). Examining the 
protein-coding potential of the V1 and V2 mRNAs showed that they are identical through 
the end of exon 20 and then diverge. V1 continues with canonical exons 21 and 22 to 
yield a 1009 AA open reading frame, while V2 lacks the sequences encoded by exons 21 
and 22 and has a different coding sequence that is responsible for a 559 AA open reading 
frame with a unique C-terminal 33 AA (Fig. 2) (4). These structural differences 
presumably have functional significance. Remarkably, DENND1A.V2 is elevated in theca 
cells of women with PCOS (7). Moreover, forced expression of DENND1A.V2 in normal 
human theca cells in culture resulted in increased expression of CYP17A1 and production 
of androgens, whereas knockdown of DENND1A.V2 mRNA in PCOS theca cells reduced 
CYP17A1 expression and androgen secretion, further supporting the notion that 
DENND1A.V2 contributes to hyperandrogenism in PCOS (7). 
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Figure 1. Schematic showing variants of DENND1A. The figure shows different 
domains, of variants of DENND1A: A 1009 amino acids DENND1A.V1 with a proline rich 
tail and 559 amino acids DENND1A.V2 with a unique 33 amino acids. Here, u-DENN and 
d-DENN are regions upstream and downstream of the DENN domain respectively. 
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Figure 2. Diagram of the 3′ end of the DENND1A gene and splicing variants 
identified taken from ‘Tee MK, Speek M, Legeza B, Modi B, Teves ME, 
McAllister JM, Strauss JF, Miller WL’. Alternative splicing of DENND1A, a PCOS 
candidate gene, generates variant 2. Mol. Cell. Endocrinol. 2016;434:25–35 . A. 
Scale diagram of ∼20 kb spanning DENND1A exons 20 and 21; bases are 
numbered starting with the first base of exon 20 (chr 9:126145934) designated as 
base 1; exons are shown as boxes. The intronic regions between exons 20 and 
20A and between exons 20A and 21 are 1490 bp and 17,897 bp, respectively. B. 
Magnified diagram of the region between exons 20 and 20A; note the difference in 
 7 
the scale bars in panels A and B. The 3′ end of miR601 (shown as a heavy black 
line) is 282 bp upstream of the hypervariable region. The heavy black line following 
exon 20A represents the DNA encoding the 3′ untranslated region of DENND1A 
V2 mRNA. 
RAB5B AND PCOS 
Among the other loci identified in PCOS GWAS studies RAB5B is a prominent one. 
RAB5B is an isoform of RAB5, which functions as a member of endocytic pathway and is 
localized in the early endosomal compartments (24). All the three isoforms of RAB5 have 
highly conserved phosphorylation consensus sites and have an 80% identity. It is 
speculated that these three isoforms can be differentially phosphorylated by different 
kinases, and this could vary the function of the three isomers (24). 
In different GWAS studies (7,25,26), it has been found that RAB5B is associated with 
PCOS. RAB5B participates in endosome formation and endocytic cycling between 
plasma membrane and early endosomes. It is possible that it could interact with the DENN 
domain of DENND1A, which is another important candidate protein for PCOS and is even 
involved in endocytosis. 
 
LHCGR AND PCOS 
LHCGR which stands for Luteinizing Hormone/Choriogonadotropin Receptor, is another 
important gene that came up in GWAS studies (7,27,28). This gene codes for the receptor 
for both luteinizing hormone and choriogonadotropin. LHCGR belongs to a G- protein 
coupled receptor-1 family whose activity is managed by the G-proteins that activate 
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adenylate cyclase. It has been found that polymorphisms involved in the LHCGR gene 
are linked with PCOS and other infertility disorders (27,29). 
LH stimulation is known to be required for the excess ovarian androgen levels in PCOS 
and RAB5 proteins are known to play a role in endocytosis and gonadotropin receptor 
signaling.  LHCGR stimulation by hCG is thought to activate the adenylate cyclase/ cyclic-
AMP pathway ultimately leading to increased androgen production (29). In a previous 
study it was found  that when human theca cells were treated with forskolin - a stimulator 
of adenylate cyclase, which ultimately activates the cAMP pathway, it leads to an increase 
of androgen production (7). Thus, it can be speculated that hCG and forskolin could 
induce steroidogenesis by a similar pathway. 
It was even seen that DENND1A plays an important role in steroidogenesis, and it was 
seen that overexpression/ knockdown of DENND1A.V2 in theca cells, results in 
augmented/ reduced CYP17A1 expression and androgen secretion (7). Thus, it is 
possible to speculate an interaction between LHCGR and DENND1A.V2, which are two 
important proteins linked to PCOS. 
 
HYPOTHESIS 
 RAB5B and LHCGR, along with DENND1A, form a network that might contribute to the 
hyperandrogenemia of PCOS. RAB5B and DENND1A, which are both involved in the 
early endocytosis processes and recycling, maybe involved in LHCGR internalization and 
processing, somehow leading to the characteristic over production of androgens, which 
is an important aspect in PCOS.    
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To explore this three protein network model, we examined the localization of 
DENND1A.V2-containing compartments and those containing LHCGR and RAB5B.  This 
thesis reports the first studies on the localization of DENND1A.V2, evidence for 
interaction among compartments containing LHCGR and RAB5B, and the unexpected 
translocation of DENND1A.V2 and RAB5B proteins into the nucleus of theca cells, raising 
the intriguing possibility that LHCGR may initiate alterations in gene expression via 
vesicular trafficking and nuclear regulation of transcription of genes involved in androgen 
synthesis. 
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CHAPTER 2 
MATERIALS & METHODS 
Cell culture  
Chinese hamster ovary (CHO) cells  
CHO cells were cultured in tissue culture dishes (60´15 mm, Corning, NY) for Western 
blot studies and Falcon 8 well chamber tissue culture slide for immunofluorescence 
studies. Cells were grown in DMEM, high glucose pyruvate medium (Thermo Fisher 
Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (Thermo Fisher 
Scientific, Waltham, MA, Catalogue number:  10437028), 1% glutamine, and 1% 
penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA). At 60-70 % confluency 
cells were transfected with pCMV6-XL5 (OriGene Technologies, Inc. Rockville, MD) for 
DENND1A.V2 expression (the vector has a CMV promoter, ampicillin resistance marker 
for selection in prokaryote host, and the DENND1A.V2 gene is inserted in MCS between 
two BamHI sites), empty vector control (pCMV-BAM); pGFP2-N2-myc-hLHCGR (kindly 
provided by Dr. Deborah Segaloff) (30) using Continuum (Gemini Bio-products, West 
Sacramento, CA). The plasmid DNA to Continuum ratios were: DENND1A.V2 (5:1); 
LHCGR (2.5:1); and pCMV-BAM (5:1). Cells were harvested or fixed 48 h after 
transfection. In some experiments, 48 h after transfection cells were washed with DMEM 
medium with serum to remove the transfection medium. Cells were treated with hCG 
(Sigma- Aldrich,  St. Louis, MO) at a concentration of 1 IU/ml for 0, 10, 30, 60, 90, 120, 
and 150 min prior to fixation.  
 
Human theca cells 
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Human theca interna tissue was obtained from follicles of women undergoing 
hysterectomy, following informed consent under a protocol approved by the Institutional 
Review Board of The Pennsylvania State University College of Medicine. As a standard 
of care, oophorectomies were performed during the luteal phase of the cycle. Theca cells 
from normal cycling and PCOS follicles were isolated and grown as we have as previously 
reported in detail (31,32).The theca cell preparations used in these studies have been 
described and characterized previously (31–39). The steroidogenic phenotypes of the 
normal and PCOS theca cells have been reported to result from the inherent properties 
of the cells, rather than the cycle phase at the time that they were isolated (33,35,40). 
PCOS and normal ovarian tissue came from age-matched women, 38–40 year old. The 
diagnosis of PCOS was made according to National Institutes of Health (NIH) consensus 
guidelines (8,41) which include hyperandrogenemia, oligoovulation, polycystic ovaries, 
and the exclusion of 21 a-hydroxylase deficiency, Cushing’s syndrome, and 
hyperprolactinemia. All of the PCOS theca cell preparations studied came from ovaries 
of women with fewer than six menses per year and elevated serum total testosterone or 
bioavailable testosterone levels (33,35,40). Each of the PCOS ovaries contained multiple 
subcortical follicles of less than 10 mm in diameter. The control (normal) theca cell 
preparations came from ovaries of fertile women with normal menstrual histories, 
menstrual cycles of 21–35 days, and no clinical signs of hyperandrogenism. Neither 
PCOS nor normal subjects were receiving hormonal medications at the time of surgery. 
Indications for surgery were dysfunctional uterine bleeding, endometrial cancer, and 
pelvic pain. Experiments comparing PCOS and normal theca were performed using 
fourth-passage (31–38 population doublings) theca cells isolated from individual size-
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matched follicles obtained from age-matched subjects, in the absence of in vivo 
stimulation. The use of fourth-passage cells allowed us to perform multiple experiments 
from the same patient population, and were propagated from frozen stocks of second 
passage cells in the media described above. The passage conditions and split ratios for 
all normal and PCOS cells were identical. Cells were grown until sub-confluent and 
treated with and without 20 μM forskolin for 16 h in defined serum-free media. Similar 
treatments with 1IU/ml hCG were performed for 0, 10, 30, 60, 90, 120, and 150 min prior 
to fixation.  
 
 
 
Rabbit polyclonal DENND1A.V2 antibody (rabbit 256 antibody) 
A rabbit polyclonal antibody against a 20 amino acid peptide ([C]-
QKSITHFAAKFPTRGWTSSSH) that is specific to DENND1A.V2, was generated by 
Thermo’s Custom Antibody Service. The specificity of this rabbit polypeptide antibody for 
the 62 kDa DENND1A.V2 protein was validated by Western blotting and antibody 
neutralization with the DENND1A.V2 peptide. 
 
Production of mouse monoclonal antibodies to DENND1A.V2 peptide 
Mouse monoclonal antibodies to the same DENND1A.V2 peptide used for the 
monoclonal antibody generation using standard procedures (7) BALB/c mice were 
immunized using KLH-coupled peptide in RIBI adjuvant. Immunizations were delivered 
both subcutaneously and intra-peritoneally in volumes of 0.05 ml per site per mouse per 
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immunization. Immunizations were given bi-weekly for 3 weeks. The final booster 
immunization was given as KLH-peptide in saline. Three days after the final booster 
immunization, mice were anesthetized using ketamine/xylazine and spleen and lymph 
nodes were removed following exsanguination. Single cell suspensions of immune cells 
were prepared and fused with P3X63-Ag8.653 myeloma cells for the production of 
hybridomas. Supernatants from cultures of hybridomas were screened by ELISA for 
reactivity to the DENND1A.V2 peptide, and to BSA-peptide. Positive cultures were 
isolated for expansion and cloning. Clones producing reactive antibodies in ELISA were 
adapted to serum free conditions using Sigma serum-free culture media. High titer 
antibodies were produced using BD Biosciences cell line devices, purified using Protein 
A/G columns (Pierce, Rockford, IL). Antibody specificity was established by Western 
blotting and antibody neutralization with the DENND1A.V2 peptide. 
 
Peptide neutralization experiments  
Primary antibody was neutralized by preincubation with the DENND1A V2 specific 
peptide ([C]-QKSITHFAAKFPTRGWTSSSH; ChinaPeptides, Shanghai, China) for 30 
min at room temperature. The peptide concentration was varied from 1 mg/ml to 0.1 
µg/ml. 
 
Immunoblotting  
Transfected cells were lysed in cold RIPA buffer (Tris (50 mM), NaCl (150 mM), NP40 
(1%), SDS (0.1%), deoxycholic acid (0.5 %), EDTA.Na2 (1 mM), pH adjusted to 8) for 30 
min at 4°C. Thirty µg protein per lane was loaded onto 10% SDS-PAGE gels, 
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electrophoretically separated, and transferred to PVDF membranes (Millipore, Billerica, 
MA) by semi-dry transference. Membranes were blocked for 1 h in 5% milk-TTBS (BIO-
RAD, Hercules, CA) and then incubated overnight with anti-DENND1A.V2 polyclonal 
rabbit antibody (256 rabbit antibody: dilution 1:1,000), mouse monoclonal anti-
DENND1A.V2 specific antibodies clones P2F5.7 and P5F9.4 (dilution 1:1,000), 
monoclonal IgG1 control antibody (dilution 1:1,000), or anti-DENND1A rabbit antibody 
(Aviva Systems Biology, Corp San Diego, CA: dilution 1:1,000). After several washes in 
1X Tris buffer saline (TBS) supplemented with 0.02% Tween 20, the membranes were 
incubated with secondary antibodies anti-rabbit IgG or anti-mouse horseradish-
peroxidase labelled (1:2,000 dilution) for 1 h at room temperature. Protein was detected 
with Super Signal Chemiluminescent Substrate (Pierce, Waltham, MA). β-actin antibody 
(Cell Signaling, Danvers, MA) was used as loading control to assure relatively equivalent 
amounts of protein were present amongst sample types. 
 
Immunofluorescence (IF) 
Transfected cells were fixed with 4% formalin for 1 h, washed with PBS twice and blocked 
with a blocking serum, containing 10% goat serum, 3% BSA and 0.2% Triton X-100. The 
cells were then incubated with anti-DENND1A.V2 rabbit polyclonal antibody (7) (dilution 
1:100), mouse monoclonal anti-DENND1A.V2 specific antibodies clones P2F5.7 and 
P5F9.4 (dilution 1:50), and same isotype monoclonal IgG1 control antibody (dilution 1:50). 
Other antibodies used for IF were (Table 1) anti-RAB5B goat antibody (LifeSpan 
BioSciences, Seattle, WA), which is a specific antibody for RAB5B and does not interact 
with RAB5A and RAB5C, and anti-LHCGR mouse antibody (Novus Biologicals, 
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Centennial, CO). For detection of primary antibodies, the cells were incubated with 
secondary antibody (anti-mouse Alexa Fluor 594 labeled, anti-rabbit Cy3-labeled, anti-
rabbit Alexa Fluor 488 labeled, anti-goat Alexa Fluor 488 labeled, or anti-mouse Alexa 
Fluor 488 labeled) for 1 h. In some experiments, before mounting the slides a Lectin 
(GNL/GNA)-Cy3-labeled (bioWORLD, Dublin, OH) was used to identify Golgi vesicles. 
The cells were then washed with PBS and mounted with VectaMount with DAPI 
(Vectorsheild, Vector Laboratories, Inc., Burlingame, CA), and then sealed with nail 
polish.  
 
Table 1: Commercial Antibodies used 
 
Sr. 
no. 
Antibody 
type 
Antibody Name Dilution Company Catalog 
Number 
1 Primary LHR Antibody IF: 1/50 Novus Biologicals, 
Centennial, CO 
NBP2-52504 
2 Primary RAB5B IF: 1/50 
WB: 1/500 
LifeSpan 
BioSciences, 
Seattle, WA 
LS-C204235 
3 Primary b-Actin WB: 1/2000 Cell Signaling 
Technology, 
Danvers, MA 
#4967 
4 Secondary anti-mouse Alexa 
Fluor 488 labeled 
IF: 1/3000 Jackson 
ImmunoResearch 
Laboratories, West 
Grove, PA 
715-547-003 
5 Secondary anti-goat Alexa 
Fluor 488 labeled 
IF: 1/3000 Jackson 
ImmunoResearch 
Laboratories, West 
Grove, PA 
705-545-147 
6 Secondary anti-rabbit Alexa 
Fluor 488 labeled 
IF: 1/3000 Jackson 
ImmunoResearch 
Laboratories, West 
Grove, PA 
711-546-152 
7 Secondary anti-rabbit Cy3-
labeled 
IF: 1/5000 Jackson 
ImmunoResearch 
Laboratories, West 
Grove, PA 
111-165-144 
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8 Secondary Galanthus nivalis 
Lectin (GNL/GNA) - 
Cy3 
30 μg/ml for 
20 min 
bioWORLD, Dublin, 
OH 
21761108-1 
 
 
9 Secondary Anti-rabbit IgG 
horseradish 
peroxide, linked 
whole antibody 
WB: 1/2000 GE Healthcare, UK 
limited, Chicago, IL 
 
NA934V 
10 Secondary Anti-mouse IgG 
horseradish 
peroxide, linked 
whole antibody 
WB: 1/2000 GE Healthcare, UK 
limited, Chicago, IL 
 
NA931V 
 
 
Imaging 
Images were captured by Zeiss LSM 700 confocal laser-scanning microscope, and 
processed by Fiji(42) and CellProfiler software(43) (NIH). In order to confirm the results, 
z-stacks were taken to span across the cell. High resolution images were also captured 
by N-SIM microscope and reconstructed by NIS-Elements AR software.  
 
Image analysis  
The nuclear/cytoplasm staining ratios were calculated using CellProfiler version-3.1.5 
software(43). Composite images were split into RGB panels and saved individually using 
Fiji(42). “Identify Primary Objects” module was used to select the nuclear area from the 
images. “Identify Secondary Objects” module was used to select the cells. This method 
finds dividing lines between clumped objects where the image stained for secondary 
objects shows a change in staining. A global threshold strategy which, calculates a single 
threshold value of the input image and uses that value to differentiate between foreground 
and background, was used to identify the secondary objects as the background of the 
image was relatively uniform. Then, “Identify Tertiary Objects” module was used to 
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identify the cytoplasm of each cell. The inputs to this module were “Edited Nucleus” and 
“Edited Cells”. The area from the “Edited Cells” was subtracted from that of the “Edited 
Nucleus” to get the object Cytoplasm. Fluorescence intensities of the selected nucleus 
and cytoplasm areas were determined and exported to an excel file using the module 
“Measure Object Intensity”. Finally, “Mean Intensity Data” was used to calculate the 
Nucleus/Cytoplasm ratio. Results were then expressed in a graph using InfoStat software 
(44). The ‘Coloc’ module of the Ziess Zen Black edition 2012, was used to estimate co-
localization. The cellular areas were selected manually for this purpose, and the 
colocalization coefficients were used for data analysis. The colocalization analysis in this 
software is done on a pixel by pixel basis and thresholds (called as crosshairs in this 
software), were set according to the guidance given in the “Acquiring and Analyzing Data 
for Colocalization Experiments in AIM or ZEN Software” manual. This method gives us 
two colocalization coefficients, one coefficient for the colocalization of Protein A vs Protein 
B, and another coefficient for Protein B vs Protein A. These values quantify how much 
protein A colocalizes with protein B and vice versa (these two coefficients can have 
different values, as the amounts of protein A and B in the analyzed area can be different). 
 
Statistical methods 
Statistical analysis were performed using InfoStat (44) software. One way ANOVA and 
Newman-Keuls as post-hoc test were used to determine if there was any significant 
difference between the Nucleus/Cytoplasm ratios in normal and PCOS theca cells, 
with/without the forskolin treatment.  
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CHAPTER 3 
 
RESULTS 
 
PART A: Polyclonal Antibody 
 
Specificity of the polyclonal anti-DENND1A.V2 antibody  
The specificity of the polyclonal anti-DENND1A.V2 antibody was evaluated by western 
blotting using whole cell lysates of CHO cells transfected with a vector expressing 
DENND1A.V2 (Fig. 3A). The antibody reacted with a protein band of the expected 
molecular weight (62 kDa) in extracts of DENND1A.V2 transfected cells, but not in empty 
vector transfected cell extracts. In both cases a non-specific band of lower molecular 
weight was detected. Additionally, the antibody was also tested in CHO cells transfected 
with DENND1A.V1 or DENND1B.V1 expressing vectors. It did not recognize V1 protein 
suggesting that it is specific to DENND1A.V2 protein (Fig. 4) The localization of 
DENND1A.V2 by IF was examined in CHO cells transfected with a plasmid expressing 
human DENND1A.V2. As shown in Figure 3B, DENND1A.V2 was localized in the 
cytoplasm of transfected cells, but no signal was detected in untransfected or empty 
vector transfected cells (data not shown). The anti-DENND1A.V2 signal was completely 
suppressed when IF was carried out with peptide-neutralized antibody (Fig. 3B).   
IF of normal human theca cells and PCOS theca cells revealed DENND1A.V2 present in 
a punctate pattern in the cytoplasm and the nucleus. The IF signals were completely 
suppressed when studies were carried out with neutralized antibody at peptide 
concentrations of 10 μg/ml and 1 μg/ml (Fig. 3C). The significant nuclear localization in 
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human theca cells differs from the pattern seen in transfected CHO cells (Fig. 3B). 
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Figure 3. Characterization of the polyclonal antibody used to detect DENND1A.V2. 
Representative full-length western blot of extracts of CHO cells transfected with a plasmid 
(pCMV6-XL5) expressing human DENND1A.V2 (+) or empty plasmid vector transfected 
cells (-). β-actin was used as a protein loading control. B. Top Panel: IF detection of 
DENND1A.V2 in transfected CHO cells. Bottom Panel: Suppression of IF in studies with 
neutralized polyclonal anti-DENND1A.V2 antibody. C. Top Panel: IF detection of 
DENND1A.V2 in normal theca cells. Bottom Panel: The absence of signal when antibody 
was neutralized with immunogenic peptide. D. Top Panel: IF detection of DENND1A.V2 
in PCOS theca cells. Bottom Panel: The absence of signal when antibody was neutralized 
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with immunogenic peptide. Size bars =10 µm. Representative images, from n number of 
experiments, where n=3. 
 
 
 
 
 
 
Figure 4. DENND1A.V2 antibody is specific for V2 and do not react with V1. Antibody 
specificity was evaluated by western blotting using total proteins extracted from CHO cells 
transfected to express DENND1A.V1 and DENND1B.V1. A, full-length blotting using 256 
rabbit antibody. Representative images, from n number of experiments, where n=3. 
 
 
Localization of DENND1A.V2 and LHCGR in transfected CHO cells.  
CHO cells were co-transfected with the human DENND1A.V2 expression plasmid and 
pGFP2-N2-myc-hLHCGR. After 48 h, the cells were fixed with 4% formalin and then 
treated with the primary 256 DENND1A.V2 polyclonal antibody. The cells were later 
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incubated with secondary Cy3-labelled anti-rabbit antibody. GFP tagged LHCGR was 
visualized directly. In the presence of LHCGR, DENND1A.V2 appears to move towards 
the plasma membrane and colocalize with LHCGR. (Fig. 5C ). However, the GFP tagged 
LHCGR maintains the same localization in presence or absence of DENND1A.V2 (Fig. 5 
B and C ). 
 
Figure 5. Localization of DENND1A.V2 and LHCGR in co-transfected CHO cells. A, 
CHO cells transfected to express DENND1A.V2, detected by polyclonal antibody. B, CHO 
cells transfected with GFP tagged human LHCGR. C, CHO cells co-transfected with 
DENND1A.V2 and LHCGR. Insert shows colocalization of DENND1A.V2 and LHCGR at 
the plasma membrane. Size bar=10µm. Representative images, from n number of 
experiments, where n=3. 
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Co-localization of LHCGR and DENND1A.V2 in transfected CHO cells and effect of 
hCG treatment. 
CHO cells were transfected with DENND1A.V2 expression plasmid, pGFP2-N2-myc-
hLHCGR, or both together. After 48 h, the cells were washed with DMEM media with 
serum to remove the transfection medium. Then the cells were treated with hCG at a 
concentration of 1 IU/ml for the time points 0, 10, 30, 60, 90, 120, and 150 min, and fixed 
after several washes. There was no appreciable change in localization of DENND1A.V2, 
in presence of hCG in the cells transfected with DENND1A.V2 alone (Fig. 6), whereas 
LHCGR was seen to move towards the peri-nuclear (presumptive Golgi) area with an 
increasing incubation time with hCG (Fig. 7). However, in presence of hCG in cells 
transfected with both DENND1A.V2 and LHCGR, DENND1A.V2 appeared to move into 
the cytoplasm, with less staining in the plasma membrane, and colocalization with 
LHCGR in the peri-nuclear area after increasing time of hCG treatment (Fig. 8). At later 
time points of hCG treatment, there appeared to be some nuclear punctate DENND1A.V2 
signals.  
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Figure 6. Time-course of hCG treatment on the localization of DENND1A.V2 in 
transfected CHO cells. Cells were treated with 1 IU/ml hCG for the time points of: A, 0 
min; B, 10 min; C, 30 min; D, 60 min; E, 90 min; F,120 min; and G, 150 min. Size bars= 
10µm. Representative images, from n number of experiments, where n=3. 
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Figure 7. Time-course of hCG treatment influences the localization of human 
LHCGR in transfected CHO cells. Cells were treated with 1 IU/ml hCG for the time 
points of: A, 0 min; B, 10 min; C, 30 min; D, 60 min; E, 90 min; F,120 min; and G, 150 
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min. White arrows point to the peri-nuclear, presumptive Golgi, area. Size bars= 10µm. 
Representative images, from n number of experiments, where n=3. 
 
 
Figure 8. Time-course of hCG treatment on the localization of DENND1A.V2 and 
LHCGR in transfected CHO cells. CHO cells were transfected to express DENND1A.V2 
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and GFP tagged LHCGR, and treated with 1 IU/ml hCG for the time points of : A, 0 min; 
B, 10 min; C, 30 min; D, 60 min; E, 90 min; F,120 min; and G, 150 min.  White arrows 
point to the peri-nuclear, presumptive Golgi, area. Size bars= 10µm. Representative 
images, from n number of experiments, where n=3. 
  
Co-localization of DENND1A.V2 and RAB5B in human theca cells.  
As noted previously, the guanine nucleotide exchange factor DENND1A is reported to 
interact with the RAB GTPase, RAB35. Given that RAB5B was identified as a PCOS 
GWAS candidate, we hypothesized that RAB5B might also interact with DENND1A, 
particularly DENND1A.V2. Thus, studies were performed to explore whether 
DENND1A.V2 co-localizes with RAB5B in normal and/or PCOS theca cells. Figure 9A 
and C shows that some DENND1A.V2 co-localizes with RAB5B in both normal and PCOS 
theca cells. High-resolution images were captured and analyzed with an N-SIM 
microscope. Figure 9E shows co-localization of DENND1A.V2 and RAB5B in vesicle-like 
structures, with a high colocalization co-efficient of about 80% for RAB5B and around 
50% for DENND1A.V2 (Fig. 9F).   
Figure 10 shows the 3D and orthogonal images of theca cells stained using anti-
DENND1A.V2 polyclonal antibody and goat polyclonal anti-RAB5B. Greater nuclear 
staining for DENND1A.V2 and RAB5B was detected in PCOS theca cells as compared 
to normal theca cells, as indicated by the orthogonal z-stack (Fig 10). 
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Figure 9. DENND1A.V2 co-localizes with the endosome protein RAB5B in normal 
and PCOS theca cells. A, Normal untreated theca cells. B, Normal Forskolin treated 
theca cells Size bars= 10µm. C, PCOS untreated theca cells. D, PCOS theca cells 
treated with 20μM forskolin. E, A representative image captured by using SIM 
microscope, showing colocalization at higher magnification. F, A graph showing percent 
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of colocalization between DENND1A.V2 and RAB5B. G, Quantification of 
nucleus/cytoplasm ratio for DENND1A.V2 expression. a Statistically significant 
differences between P vs N without forskolin treatment, p= 0.006. b Statistically 
significant differences between 0μM vs 20μM forskolin treatment, p=0.0001 (One way 
ANOVA and Newman-Keuls as post-hoc test). H, Quantification of nucleus/cytoplasm 
ratio for RAB5B expression. a Statistically significant differences between P vs N without 
forskolin treatment, p=0.0001. b Statistically significant differences between 0μM vs 
20μM forskolin treatment, p=0.0001 (One way ANOVA and Newman-Keuls as post-hoc 
test). Representative images, from n number of experiments, where n=3. 
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Figure 10. 3D reconstruction image showing colocalization of DENND1A.V2 and 
RAB5B in the cytoplasm as well as the nucleus of normal and PCOS theca cells. 
Top panels show 3D side view and bottom panels show 2D front and z stack view for x 
and y coordinates. A normal untreated cells; C, PCOS theca cells. Representative 
images, from n number of experiments, where n=3. 
 
 
The effect of hCG treatment on DENND1A.V2, RAB5B and LHCGR localization in 
normal and PCOS theca cells. 
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To determine if there was any change in localization of DENND1A.V2 RAB5B and 
LHCGR in normal and PCOS theca cells treated with hCG at various time points. Normal 
and PCOS theca cells were treated with hCG at a concentration of 1 IU/ml for 0, 10, 30, 
60, 90, 120, and 150 min, and were fixed at the appropriate time points. In normal theca 
cells, was observed that DENND1A.V2 and RAB5B colocalize, but the percentage of 
colocalization was unaffected in response to hCG treatment (Fig. 11H and I). However, 
DENND1.V2 and LHCGR showed increases in the percentage of colocalization at 150 
min of hCG treatment (Fig.13H). In addition, hCG treatment seems to have influenced 
translocation of DENND1A.V2, RAB5B and LHCGR towards the Golgi area, with 
increasing time of hCG treatment (indicated by arrows in figures 11 and 13). Similar 
results were observed with PCOS theca cells. However, DENND1A.V2, RAB5B and 
LHCGR movement was delayed to a later time point than that observed in normal theca 
cells (Fig. 12 and 14). The percentage of colocalization of DENND1A.V2 and LHCGR 
was significantly lower at 90 and 120 minutes of hCG treatment (Fig. 14H), perhaps 
reflecting different kinetics of protein/vesicle compartment movement. 
Z-stack analysis was performed to determine whether LHCGR entered into the nucleus 
and no nuclear receptor was detected (Fig.15). In order to verify that DENND1A.V2, 
RAB5B and LHCGR were localizing in the Golgi, cells were stained with Cy3-labeled 
lectin specific for Golgi and Golgi vesicles. Figure 16 shows some colocalization of all 
three proteins with a lectin Golgi vesicle marker.  
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 Figure 11: Time-course of hCG treatment of normal theca cells on the localization 
of DENND1A.V2 and RAB5B. Cells were treated with 1 IU/ml hCG for the time points 
of: A, 0 min; B, 10 min; C, 30 min; D, 60 min; E, 90 min; F,120 min; and G, 150 min.  
White arrows point to peri-nuclear areas. Size bars =10µm. H, Graph showing high 
colocalization co-efficient of about 90% for RAB5B with DENND1A.V2 and around 45% 
for DENND1A.V2 with RAB5B in Golgi area. I, Graph showing high colocalization co-
efficient of about 90% for RAB5B with DENND1A.V2 and around 30% for DENND1A.V2 
with RAB5B in nucleus. Representative images, from n number of experiments, where 
n=3. 
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 Figure 12. Time-course of hCG treatment of PCOS theca cells and the localization 
of DENND1A.V2 and RAB5B. Cells were treated with 1 IU/ml hCG for the time points of: 
A, 0 min; B, 10 min; C, 30 min; D, 60 min; E, 90 min; F,120 min; and G, 150 min. White 
arrows point to peri-nuclear areas. Size bars =10µm. H, Graph showing high 
colocalization co-efficient of about 80% for RAB5B with DENND1A.V2 and around 30% 
for DENND1A.V2 with RAB5B in Golgi area. I, Graph showing high colocalization co-
efficient of about 80% for RAB5B with DENND1A.V2 and around 25% for DENND1A.V2 
with RAB5B in nucleus. Representative images, from n number of experiments, where 
n=3. 
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Figure 13. Time-course of hCG treatment of normal theca cells on localization of 
DENND1A.V2 and LHCGR. Cells were treated with 1 IU/ml hCG for the time points of: 
A, 0 min; B, 10 min; C, 30 min; D, 60 min; E, 90 min; F,120 min; and G, 150 min. White 
arrows point to peri-nuclear areas. Size bars =10µm. H, Graph showing high 
colocalization co-efficient of about 70% for LHCGR with DENND1A.V2 and around 35% 
for DENND1A.V2 with RAB5B in peri-nuclear area. Representative images, from n 
number of experiments, where n=3. 
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Figure 14. Time-course of hCG treatment of PCOS theca cells and the localization 
of DENND1A.V2 and LHCGR. Cells were treated with 1 IU/ml hCG for the time points 
of: A, 0 min; B, 10 min; C, 30 min; D, 60 min; E, 90 min; F,120 min; and G, 150 min. 
Increasing concentrations of hCG drives DENND1A.V2 and LHCGR movement towards 
the Golgi area (white arrows) but at a latter time point than that with normal theca cells. 
H, Graph showing high colocalization co-efficient of about 70% for LHCGR with 
DENND1A.V2 and around 40% for DENND1A.V2 with RAB5B in peri-nuclear area. 
Representative images, from n number of experiments, where n=3. 
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Figure 15: Representative figures of DENND1A.V2, RAB5B and LHCGR localizing 
in the Golgi. A, DENND1A.V2 with Golgi vesicles. B, RAB5B with Golgi vesicles. C 
LHCGR with Golgi vesicles. 
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Figure 16. Representative 3D reconstruction image showing LHCGR does not enter 
nucleus. Top panels show 3D side view and bottom panels show 2D front and z stack 
view for x and y coordinates for untreated PCOS cells. 
 
Effect of forskolin treatment on localization of DENND1A.V2 and RAB5B in human 
theca cells. 
The hCG-triggered movement of DENND1A.V2 and the increased nuclear localization of 
DENND1A.V2 in the nuclei of PCOS theca cells raised the possibility that the nuclear 
accumulation of DENND1A.V2 might be the result of altered signal transduction involving 
cAMP, which is known to stimulate thecal androgen production. To evaluate this 
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possibility, normal and PCOS theca cells were treated with or without 20µM forskolin for 
24 h prior to fixation to determine if there is difference in localization of DENND1A.V2 and 
RAB5B (Fig. 9B and D). It has been previously shown that forskolin treatment increases 
theca cell androgen biosynthesis and expression of genes encoding enzymes involved in 
androgen production (7). In the presence of forskolin, the PCOS theca cells showed 
significantly more nuclear staining for DENND1A.V2 and RAB5B (higher N/C ratio) 
(Figure 9G and H). However, there was no significant change in normal theca cells in the 
case of RAB5B. 
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PART B: Monoclonal Antibodies 
 
Specificity of the monoclonal anti-DENND1A.V2 antibody and its use in 
immunofluorescence studies (IF). 
Specificity of anti-DENND1A.V2 antibodies was evaluated by western blot using the 
whole cell lysates of CHO cells transfected with a vector expressing DENND1A.V2. It was 
observed all the two antibodies correctly detected the protein of  interest (Fig. 17). 
Additionally, these antibodies were also tested in CHO cells transfected with 
DENND1A.V1 or DENND1B.V1 expressing vectors. None of these two antibodies 
recognized V1 protein suggesting they are specific to DENND1A.V2 protein (Fig. 18). The 
localization of DENND1A.V2 by IF was examined in CHO cells transfected with a plasmid 
expressing human DENND1A.V2 (pCMV6-XL5). Some DENND1A.V2 was localized to 
the plasma membrane, but the majority was in the cytoplasm of transfected cells using 
monoclonal anti-DENND1A.V2 antibodies. The signals were completely suppressed 
when IF was carried out with peptide-neutralized antibodies (Fig. 19). In transfected CHO 
cells, there was no nuclear staining, verified when z-stack images were obtained (Fig. 
20). 
The two mouse monoclonal antibodies detected DENND1A.V2 in patterns identical to the 
rabbit polyclonal antibody in transfected CHO cells, but the monoclonal antibodies gave 
no signal in IF staining of human theca cells (data not shown).  These disparities suggest 
that there may be structural differences in the DENND1A.V2 C-terminus in theca cells 
(e.g., post-translational modification), or antigen masking due to protein-protein 
interaction, which prevent interaction with the monoclonal antibodies.  Another possibility 
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could be that the monoclonal antibodies are more specific but less sensitive than the 
polyclonal antibody. 
 
 
 
Figure 17: Characterization of antibodies used to detect DENND1A.V2. 
Representative full-length western blottings of CHO cells transfected to express 
DENND1A.V2. All the antibodies used specifically recognize the 62kDa DENND1A.V2 
protein. Representative β-Actin for each blotting are shown in the lower panels, A. P2F5.7 
mouse monoclonal antibody. B, P5F9.4 mouse monoclonal antibody. C, IgG control 
mouse monoclonal antibody. +CHO cells transfected with pCMV6-XL5 plasmid to express 
DENND1A.V2 as the positive control. -CHO cells transfected with empty vector pCMV-
BAM, as a negative control. 
 
 
62kDa 
DENND1A.V2 
 
42kDa 
         ß- actin 
A B C 
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Figure 18: DENND1A.V2 monoclonal antibodies are specific for DENND1A.V2 and  
do not react with DENND1A.V1. Antibody specificity was evaluated by western blotting 
using total proteins extracted from CHO cells transfected to express DENND1A.V1 and 
DENND1B.V1. A, using P2F5.7 mouse monoclonal antibody. B, P5F9.4 mouse 
monoclonal antibody. - Empty vector pCMV-BAM, as a negative control. DENND1A.V1 
using pCMV Tag2B plasmid. DENND1B.V1 using human pCDNA3-FLAG. + 
DENND1A.V2 using pCMV6-XL5 plasmid as positive control. 
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Figure 19: DENND1A.V2 localizes in the cytoplasm of transfected CHO cells.  
CHO cells were transfected with pCMV6-XL5 plasmid to characterize the subcellular 
localization of DENND1A.V2 . A,  DENND1A.V2 detection by P2F5.7 mouse monoclonal 
antibody. B, Peptide neutralization assay for P2F5.7 mouse monoclonal antibody. C, 
DENND1A.V2 detection by P5F9.4 mouse monoclonal antibody. D, Peptide 
neutralization assay for P5F9.4 mouse monoclonal antibody. Representative images, 
from n number of experiments, where n=3. 
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Figure 20. 3D reconstruction image showing that DENND1A.V2 localizes only in the 
cytosolic portion of transfected CHO cells. Top panels show 3D side view and bottom 
panels show 2D front and z stack view for x and y coordinates. A,  CHO cells expressing 
DENND1A.V2, detected by P2F5.7 mouse monoclonal antibody. B, detection by P5F9.4 
mouse monoclonal antibody. Representative images, from n number of experiments, 
where n=3. 
A 
B 
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CHAPTER 4 
 
RESULTS SUMMARY 
 
 
1. In CHO cells, DENND1A.V2 was localized in the cytoplasm of transfected 
cells with was no nuclear staining  
2. In human theca, DENND1A.V2 was detected in a puncta pattern in the 
cytosol and nucleus, with significantly more DENND1A.V2 nuclear staining in 
untreated PCOS theca cells  
3. Co-transfection of DENND1A.V2 and LHCGR in CHO cells, translocates 
DENND1A.V2 to plasma membrane  
4. With increasing time-points of hCG in CHO cells transfected with 
DENND1A.V2 and LHCGR , DENND1A.V2 seems to be more in the entire 
cytoplasm and less in the membrane whereas LHCGR was seen to move 
towards the perinuclear area 
5. With increasing time-points of hCG in theca cells,  DENND1A.V2, RAB5B and 
LHCGR seems to to move towards the perinuclear area  
6. After treatment with forskolin, significant translocation was observed for 
DENND1A.V2 in both Normal and PCOS theca cells, and RAB5B in only 
PCOS theca cells 
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CHAPTER 5 
 
 
DISCUSSION  
 
Over the past decade convincing evidence has accumulated regarding genetic factors 
that contribute to PCOS. The studies of genetic and molecular factors involved in the 
pathophysiology of PCOS accelerated after milestone GWAS studies identified PCOS 
candidate loci including those near DENND1A, INSR, YAP1, C9orf3, RAB5B, HMGA2, 
TOX3, SUMO1P1/ZNF217, THADA and LHCGR (14–18). Truncated splice variant of 
PCOS GWAS candidate gene DENND1A, termed DENND1A.V2, was shown to increase 
the expression in PCOS theca cells (4,7). DENND1A has been described as a clathrin 
binding protein, that most likely is related to gonadotropin receptor signaling as part of the 
clustering and endocytosis of plasma membrane receptors via the involvement of RAB5 
proteins (45,46).   
The functional importance of DENND1A.V2 in the PCOS phenotype of human theca cells 
was established by demonstrating that increased DENND1A.V2 stimulates androgen 
synthesis by normal theca cells and knock-down of DENND1A.V2 diminishes androgen 
production in PCOS theca cells (7). Although these studies provided evidence for a direct 
role for DENND1A.V2 in production of the ovarian PCOS phenotype, the mechanisms of 
DENND1A.V2 action and the relationship of DENND1A.V2 to other PCOS candidate 
genes was unknown. Moreover, little was known about DENND1A.V2 and its cellular 
location in normal and PCOS theca cells until the present studies.  
Based on the available information on the function of DENND1A, its clathrin-binding 
domain, the role of the DENN domain as a guanine nucleotide exchange factor, the critical 
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role of LH action in theca cell androgen production, as well as the existing literature on 
the role of RAB5 proteins in gonadotropin receptor function; it is possible to propose that 
LHCGR, DENND1A.V2 and RAB5B function in a network to create the ovarian theca cell 
PCOS phenotype (26). Consistent with this hypothesis, this thesis provides the first 
cytological evidence to demonstrate interactions of cellular compartments containing 
LHCGR, DENND1A.V2 and RAB5B using transfected CHO cells, and well characterized 
cultured theca cells obtained from the ovaries of normal cycling and PCOS women. Based 
on these combined observations, this thesis demonstrated that LHCGR and 
DENND1A.V2 are co-localized on the plasma membrane, and that DENND1A.V2 is also 
co-localized with RAB5B in the endocytic vesicle, and peri-nuclear area. Furthermore, 
following hCG/forskolin stimulation, DENND1A.V2 translocates to the peri-nuclear region 
and nucleus to a larger extent in PCOS theca cells as compared to normal cells and may 
subsequently mediate increased expression of CYP17A1 and CYP11A, leading to 
hyperandrogenism in PCOS theca cells. These studies also suggest that the nuclear 
localization of DENND1A.V2 and RAB5B may mediate changes in signaling in PCOS 
theca cells that may contribute to alterations in gene expression.  
Relatively little is known about the role of RAB5B in gonadotropin receptor trafficking, as 
most studies have focused on the highly related RAB5A protein, which is thought to 
participate in both FSHR and LHCGR endocytosis and signaling (45). However, it is 
known that RAB5B is involved in phosphatidyl inositol 3 kinase (PI3K), protein kinase B 
(PKB/AKT), and mitogen activated protein kinase (MAPK/ERK) signaling pathways, 
which could play important roles in LHCGR stimulation of steroidogenesis (47).  
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The most unexpected observation was the detection of DENND1A.V2 in the nuclei of 
theca cells, with PCOS theca cells showing a greater nuclear accumulation than normal 
theca cells. The nuclear translocation of DENND1A.V2 was stimulated by forskolin, 
suggesting that the translocation process is cAMP-dependent. RAB5B was co-localized 
with DENND1A.V2 in the nucleus of PCOS theca cells, with greater accumulation in the 
nuclei of forskolin-stimulated cells. It is noteworthy that in earlier studies using 
immunoperoxidase staining of sections of normal and PCOS ovaries both cytoplasmic 
and nuclear DENND1A.V2 staining in theca interna were detected (7), which is consistent 
with IF studies on cultured theca cells showed here. 
The entry of DENND1A.V2 and RAB5B into the nucleus suggests that these proteins may 
participate in the regulation of steroidogenic enzyme genes beyond their roles in the 
plasma membrane and cytoplasmic endocytic vesicles, perhaps in part explaining the 
increased transcription of CYP11A1 and CYP17A1 associated with the elevated level of 
DENND1A.V2 protein in PCOS theca cells and the effects of forced DENND1A.V2 
expression in normal theca cells. Future studies should explore the molecules that 
interact with DENND1A.V2 and RAB5B in the nucleus of PCOS theca cells and their 
relationship to chromatin. One possible mechanism of gene regulation involves APPL1, 
a multifunctional endosomal adaptor protein interacts with RAB5 molecules. APPL1 is 
translocated into the nucleus, where it has been shown to modulate histone deacetylases, 
participate in nucleosome remodeling and gene transcription (48). 
Thus, in future some immunoprecipitation would help to understand what DENND1A.V2 
and RAB5B are doing inside the nucleus, and how are they interacting with other 
molecules and are associated with increasing the expression of CYP11A1 and CYP17A1. 
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The discovery that DENND1A.V2 and RAB5B both enter the nucleus, with more 
prominent nuclear localization in PCOS theca cells, raises the possibility that LHCGR 
signaling also occurs at multiple locations in theca cells, and that quantitative differences 
in DENND1A.V2 and its nuclear translocation explain phenotypic differences between 
normal and PCOS theca cells. These findings also raise many unanswered questions 
regarding the translocation including the nature of the nuclear localization signal and how 
the movement of DENND1A.V2 is increased by cAMP. 
In summary, we have identified a network involving genes encoded by three different loci 
associated with PCOS. Figure 20 presents a schematic of how these three proteins 
and/or their compartments might be interacting with each other. DENND1A.V2 and 
RAB5B are both involved in the early endocytic pathways. Thus, their proximity to each 
other followed by the observation of their movement into the nucleus after treatment by 
forskolin suggests that they may be working together to increase the androgen production 
inside the cells. LHCGR which is a receptor for both LH and hCG, and is known to activate 
the cAMP pathway, in presence of hCG to increase the androgen production in the cells. 
Thus, this identified network involves proteins including LHCGR, DENND1A.V2 and 
RAB5B that are plausible determinants of the theca cell phenotype of excess androgen 
production. It should be noted that this model is based on static images and cannot 
provide details regarding the specific itineraries that each protein follows. It is clear 
however, that both DENND1A.V2 and RAB5B enter into the nucleus, and that represents 
an unexpected destination. It remains to be determined whether DENND1A.V2 and 
RAB5B play roles in signaling though other plasma membrane receptors including FSHR 
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and INSR, which have also been implicated in GWAS and other genetic studies to be 
involved in the pathophysiology of PCOS. 
 
 
Figure 20. Schematic showing the proposed network involving dynamic changes 
in the interaction and trafficking of LHCGR, DENND1A.V2, and RAB5B through 
various cellular compartments, resulting in the hyperandrogenism associated with 
PCOS. As shown, LH/hCG binding to the LH-receptor (LHCGR), or forskolin-stimulation 
(F), results in the interaction between the GEF, DENND1A.V2 in the clathrin coated pit of 
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the lipid bilayer with the GTPase, RAB5B, resulting in movement of LHCGR, 
DENND1A.V2 and RAB5B to the early endocytic vesicles. LHCGR is subsequently 
recycled to the cellular membrane from the endocytic vesicles. This is followed by 
successive trafficking of LHCGR, DENND1A.V2 and RAB5B into the Golgi, and 
movement of DENND1A.V2 and RAB5B into the nucleus, resulting in increased 
transcription of the CY17A1 and CYP11A1, along with the cAMP signaling pathway, and 
augmented androgen production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 56 
CHAPTER 6 
 
 
REFERENCES 
 
1.  Rodgers R, Avery J, Moore V, Davies M, Azziz R, Stener-Victorin E, Moran L, 
Robertson S, Stepto N, Norman R, Teede HJ. Complex diseases and co-
morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocr. 
Connect. 2019 8(3): R71–R75. 
2.  Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term 
health. Fertil. Steril. 2018;110(5):794–809. 
3.  Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, Lizneva D, 
Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat. 
Rev. Dis. Prim. 2016;2:16057. 
4.  Tee MK, Speek M, Legeza B, Modi B, Teves ME, McAllister JM, Strauss JF, 
Miller WL. Alternative splicing of DENND1A, a PCOS candidate gene, generates 
variant 2. Mol. Cell. Endocrinol. 2016;434:25–35. 
5.  Balen A, Homburg R, Franks S. Defining polycystic ovary syndrome. BMJ 
2009;338. doi:10.1136/bmj.a2968. 
6.  Dunaif A. Genes, aging and sleep apnea in polycystic ovary syndrome. Nat. Rev. 
Endocrinol. 2011;8:72. 
7.  McAllister JM, Modi B, Miller BA, Biegler J, Bruggeman R, Legro RS, 
Strauss JF. Overexpression of a DENND1A isoform produces a polycystic ovary 
syndrome theca phenotype. Proc. Natl. Acad. Sci. 2014;111(15):E1519–E1527. 
8.  Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), 
 57 
Diagnostic Criteria, and AMH. Asian Pac. J. Cancer Prev. 2017;18(1):17–21. 
9.  Homburg R. The management of infertility associated with polycystic ovary 
syndrome. Reprod. Biol. Endocrinol. 2003;1:1–9. 
10.  Januszewski M, Issat T, Jakimiuk AA. Metabolic and hormonal effects of a 
combined Myo-inositol and D-chiro-inositol therapy on patients with polycystic 
ovary syndrome ( PCOS ). 2019;90(1):7–10. 
11.  Bo-Jeong P, Yang H, Sohn E, Yi Yu S, Lee D, Jung DH, Ko BS, Lee HW. 
Tetragonia tetragonioides (pall.) kuntze regulates androgen production in a 
letrozole-induced polycystic ovary syndrome model. Molecules 2018;23(5). 
doi:10.3390/molecules23051173. 
12.  Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic 
basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. 
U. S. A. 1998;95(25):14956–14960. 
13.  Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic 
ovary syndrome in a Dutch twin-family study. J. Clin. Endocrinol. Metab. 
2006;91(6):2100–2104. 
14.  Liu H, Zhao H, Chen ZJ. Genome-Wide Association Studies for Polycystic Ovary 
Syndrome. Semin. Reprod. Med. 2016;34(4):224–229. 
15.  Chen Z-J, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J, Liang 
X, Zhao X, Zhao J, Sun Y, Zhang B, Jiang H, Zhao D, Bian Y, Gao X, Geng L, 
Li Y, Zhu D, Sun X, Xu J, Hao C, Ren C, Zhang Y, Chen S, Zhang W, Yang A, 
Yan J, Li Y, Ma J, Zhao Y. Genome-wide association study identifies 
susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 
 58 
and 9q33.3. Nat. Genet. 2010;43:55. 
16.  Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, Zhang B, Liang X, Li T, Chen J, 
Shen J, Zhao J, You L, Gao X, Zhu D, Zhao X, Yan Y, Qin Y, Li W, Yan J, 
Wang Q, Zhao J, Geng L, Ma J, Zhao Y, He G, Zhang A, Zou S, Yang A, Liu J, 
Li W, Li B, Wan C, Qin Y, Shi J, Yang J, Jiang H, Xu JE, Qi X, Sun Y, Zhang 
Y, Hao C, Ju X, Zhao D, Ren CE, Li X, Zhang W, Zhang Y, Zhang J, Wu D, 
Zhang C, He L, Chen ZJ. Genome-wide association study identifies eight new 
risk loci for polycystic ovary syndrome. Nat. Genet. 2012;44(9):1020–1025. 
17.  Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, Karaderi 
T, Barber TM, McCarthy MI, Franks S, Lindgren CM, Welt CK, Diamanti-
Kandarakis E, Panidis D, Goodarzi MO, Azziz R, Zhang Y, James RG, Olivier 
M, Kissebah AH, Stener-Victorin E, Legro RS, Dunaif A, Alvero R, Barnhart 
HX, Baker V, Barnhart KT, Bates GW, Brzyski RG, Carr BR, Carson SA, 
Casson P, Cataldo NA, Christman G, Coutifaris C, Diamond MP, Eisenberg 
E, Gosman GG, Giudice LC, Haisenleder DJ, Huang H, Krawetz SA, Lucidi S, 
McGovern PG, Myers ER, Nestler JE, Ohl D, Santoro N, Schlaff WD, Snyder 
P, Steinkampf MP, Trussell JC, Usadi R, Yan Q, Zhang H. Genome-wide 
association of polycystic ovary syndrome implicates alterations in gonadotropin 
secretion in European ancestry populations. Nat. Commun. 2015;6(May 2015):1–
12. 
18.  Chen LI, Hu L, Wang Y, Yang H, Huang X. Genome-wide association study for 
SNPs associated with PCOS in human patients. 2017;(14):4896–4900. 
19.  Goodarzi MO, Jones MR, Li X, Chua AK, Garcia O, Chen DI, Krauss RM, 
 59 
Rotter JI, Ankener W, Legro RS, Azziz R, Iii JFS, Dunaif A, Urbanek M. with 
Polycystic Ovary Syndrome in European Cohorts. 2013;49(2):90–95. 
20.  Louwers Y V., Stolk L, Uitterlinden AG, Laven JSE. Cross-Ethnic meta-
Analysis of genetic variants for polycystic ovary syndrome. J. Clin. Endocrinol. 
Metab. 2013;98(12):2006–2012. 
21.  Marat AL, McPherson PS. The connecdenn family, Rab35 guanine nucleotide 
exchange factors interfacing with the clathrin machinery. J. Biol. Chem. 
2010;285(14):10627–10637. 
22.  Kulasekaran G, Nossova N, Marat AL, Lund I, Cremer C, Ioannou MS, 
McPherson PS. Phosphorylation-dependent regulation of connecdenn/DENND1 
guanine nucleotide exchange factors. J. Biol. Chem. 2015;290(29):17999–18008. 
23.  Ye B, Duan B, Deng W, Wang Y, Chen Y, Cui J, Sun S, Zhang Y, Du J, Gu L, 
Lin L, Tang Y. EGF stimulates Rab35 activation and gastric cancer cell migration 
by regulating DENND1A-Grb2 complex formation. Front. Pharmacol. 
2018;9(NOV):1–12. 
24.  Chiariello M, Bruni CB, Bucci C, Nazionale C, Pansini VS. The small GTPases 
Rab5a , Rab5b and Rab5c are differentially phosphorylated in vitro. FEBS Letters. 
1999;453:20–24. 
25.  Sun Y, Yuan Y, Yang H, Li J, Feng T, Ouyang Y, Jin T, Liu M. Association 
between Common Genetic Variants and Polycystic Ovary Syndrome Risk in a 
Chinese Han Population. J Clin Res Pediatr Endocrinol. 2016;8(4):405–410. 
26.  Mcallister JM, Legro RS, Modi BP, State P. HHS Public Access. 
2016;26(3):118–124. 
 60 
27.  Liu N, Ma Y, Wang S, Zhang X, Zhang Q, Zhang X, Fu L, Qiao J. Association of 
the genetic variants of luteinizing hormone, luteinizing hormone receptor and 
polycystic ovary syndrome. Reprod. Biol. Endocrinol. 2012;10:1–7. 
28.  Zhou Y-C, Fu Q-G, Zhao R-Q, Ni Y-D, Chen J. [Expression of mRNAs for GHR, 
IGF-IR, FSHR and LHR in granulosa and theca layers of ovarian follicles of 
Shaoxing ducks]. Yi Chuan Xue Bao 2003;30(9):840—846. 
29.  Choi J, Smitz J. Luteinizing hormone and human chorionic gonadotropin: Origins 
of difference. Mol. Cell. Endocrinol. 2014;383(1–2):203–213. 
30.  Zhang M, Guan R, Segaloff DL. Revisiting and Questioning Functional Rescue 
between Dimerized LH Receptor Mutants. Mol. Endocrinol. 2012;26(4):655–668. 
31.  Wickenheisser JK, Biegler JM, Nelson-DeGrave VL, Legro RS, Strauss JF, 
McAllister JM. Cholesterol Side-Chain Cleavage Gene Expression in Theca 
Cells: Augmented Transcriptional Regulation and mRNA Stability in Polycystic 
Ovary Syndrome. PLoS One 2012;7(11). doi:10.1371/journal.pone.0048963. 
32.  Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, Asano T, Fujishiro M, 
Legro RS, Kimball SR, Strauss JF, McAllister JM. Alterations in Mitogen-
Activated Protein Kinase Kinase and Extracellular Regulated Kinase Signaling in 
Theca Cells Contribute to Excessive Androgen Production in Polycystic Ovary 
Syndrome. Mol. Endocrinol. 2005;19(2):379–390. 
33.  Nelson VL, Legro RS, Iii JFS, Mcallister JM. a Stable Steroidogenic Phenotype 
of Propagated Theca Cells from Polycystic Ovaries. :946–957. 
34.  Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, 
Strauss JF, McAllister JM. The biochemical basis for increased Testosterone 
 61 
production in theca cells propagated from patients with polycystic ovary 
syndrome. J. Clin. Endocrinol. Metab. 2001;86(12):5925–5933. 
35.  Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Iii JFS, Mcallister JANM. 
Differential Activity of the Cytochrome P450 17 ␣ - Hydroxylase and 
Steroidogenic Acute Regulatory Protein Gene Promoters in Normal and 
Polycystic Ovary Syndrome Theca Cells *. 2000;85(6):2304–2311. 
36.  Strauss JF. Some new thoughts on the pathophysiology and genetics of 
polycystic ovary syndrome. Ann. N. Y. Acad. Sci. 2003;997:42–48. 
37.  Wickenheisser JK, Nelson-DeGrave VL, Quinn PG, McAllister JM. Increased 
Cytochrome P450 17α-Hydroxylase Promoter Function in Theca Cells Isolated 
from Patients with Polycystic Ovary Syndrome Involves Nuclear Factor-1. Mol. 
Endocrinol. 2004;18(3):588–605. 
38.  Wood JR, Ho CKM, Nelson-Degrave VL, McAllister JM, Strauss JF. The 
molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by 
gene expression profiling. J. Reprod. Immunol. 2004;63(1):51–60. 
39.  Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbanek M, McAllister JM, 
Mosselman S, Strauss JF. The molecular phenotype of polycystic ovary 
syndrome (PCOS) theca cells and new candidate PCOS genes defined by 
microarray analysis. J. Biol. Chem. 2003;278(29):26380–26390. 
40.  Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, Wood JR, Legro RS, 
Strauss JF, McAllister JM. Valproate Potentiates Androgen Biosynthesis in 
Human Ovarian Theca Cells. Endocrinology 2004;145(2):799–808. 
41.  Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, 
 62 
Welt CK. Diagnosis and treatment of polycystic ovary syndrome: An endocrine 
society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98(12):4565–
4592. 
42.  Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, 
Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, 
Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: An open-source 
platform for biological-image analysis. Nat. Methods 2012;9(7):676–682. 
43.  Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, 
Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM. 
CellProfiler: image analysis software for identifying and quantifying cell 
phenotypes. Genome Biol. 2006;7(10):R100. 
44.  Balzarini M, Gonzalez L, Tablada M, Casanoves F, Di Rienzo J, Robledo C. 
Infostat: manual del usuario.; 2008. 
45.  Gulappa T, Clouser CL, Menon KMJ. The role of Rab5a GTPase in endocytosis 
and post-endocytic trafficking of the hCG-human luteinizing hormone receptor 
complex. Cell. Mol. Life Sci. 2011;68(16):2785–2795. 
46.  Bowersox S, Chen S, Beard G, Jean-Alphonse F, Hanyaloglu AC, 
Puthenveedu MA. Spatially Restricted G Protein-coupled Receptor Activity via 
Divergent Endocytic Compartments. J. Biol. Chem. 2013;289(7):3960–3977. 
47.  Wilson DB, Wilson MP. Identification and subcellular localization of human rab5b 
, a new member of the ras-related superfamily of GTPases . J Clin Invest . 
1992;89(3):996–1005. 
48.  Rashid S, Pilecka I, Torun A, Olchowik M, Bielinska B, Miaczynska M. 
 63 
Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-
catenin/TCF-mediated transcription. J. Biol. Chem. 2009;284(27):18115–28. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
VITA 
 
Rewa Kulkarni was born in Aurangabad, Maharashtra, India on 26th of November 1995. 
She graduated high school in 2013. She received her Bachelor in Technology, and 
Biotechnology, from Savitribai Phule University (Previously known as University of 
Pune), India in 2017 before enrolling in the graduate school at Virginia Commonwealth 
University.  
 
 
